

Special Issue

Flavivirus Immunotherapy

Message from the Guest Editor

As the of the Vaccines Special Issue “Flavivirus Immunotherapy”, I would like to invite you to contribute with an original report, original observation, commentary, or review to it. As you are perfectly aware, flaviviruses (Flaviviridae family) are arthropod-borne viruses, whose genomes are composed of a single RNA molecule of positive polarity. Vaccines are only available for a few flaviviruses and there is no specific therapy on the market for any of them. Thereby, to achieve a more comprehensive understanding of the current trends in flavivirus immunoprophylaxis, this Special Issue of Vaccines is dedicated to recent scientific and technical progress made in this field. Based on your extensive experience and your recent publications, it would be our honor to publish your work to support the global scientific community. We sincerely hope that you accept our invitation. If you can contribute, please let us know at your earliest convenience, and we will provide you with additional details.

Guest Editor

Prof. Dr. Juan Carlos Saiz

Department of Biotechnology, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), Madrid, Spain

Deadline for manuscript submissions

closed (31 March 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/66379

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).